The ATP9A Knockout HT29 Polyclonal Cells consist of a CRISPR/Cas9-edited polyclonal cell population derived from the HT29 human colorectal adenocarcinoma line, designed for constitutive disruption of the ATP9A gene. This product provides a genetically heterogeneous loss-of-function model to investigate ATP9A-dependent processes without clonal isolation bias, enabling robust functional studies in intestinal epithelial biology.
HT29 cells are epithelial-like cells originally isolated from a human colorectal adenocarcinoma, widely employed as a model system for intestinal epithelial barrier function, ion transport, and colorectal cancer research. Their well-characterized growth properties and relevance to mucosal biology make them a suitable host for examining the consequences of ATP9A ablation in a disease-relevant cellular context.
ATP9A encodes a P4-ATPase lipid flippase that, in a heterodimeric complex with its obligatory ??-subunit CDC50A (TMEM30A), translocates aminophospholipids from the exoplasmic to the cytoplasmic leaflet of endosomal and lysosomal membranes. This activity is regulated by phosphoinositides such as PI3P, calcium signaling, and protein kinase D, and facilitates interactions with adaptor protein AP-1, clathrin, and sorting nexin (SNX) family proteins. ATP9A-mediated lipid asymmetry is essential for membrane budding and fission events that drive endosomal sorting, lysosomal acidification, and autophagic flux. Disruption of ATP9A leads to aberrant phosphatidylserine externalization, impaired ESCRT machinery recruitment, and accumulation of markers including LAMP1 and LC3-II, highlighting its central role in the endolysosomal and autophagy network.
In the HT29 colorectal adenocarcinoma background, ATP9A knockout creates a pertinent model for dissecting how defective lipid flippase activity contributes to pathological endosomal-lysosomal trafficking. The model facilitates exploration of ATP9A??s impact on colorectal cancer cell proliferation, migration, and drug resistance, processes intimately linked to autophagy and lysosomal function. Additionally, it serves as a platform for studying neurodegenerative and lipid storage disorder mechanisms associated with ATP9A dysfunction.
Research applications span endosomal trafficking analysis via transferrin uptake assays, autophagy flux measurement through LC3 turnover in the presence of chloroquine, lysosomal pH monitoring with LysoSensor, and functional characterization of colorectal cancer behavior using MTS proliferation and wound-healing migration assays. Flow cytometry enables assessment of phosphatidylserine exposure (annexin V) and cell cycle distribution. This polyclonal knockout population is particularly suited for high-throughput drug screens targeting ATP9A-related pathways. For further technical details or batch-specific inquiries, please contact Ascent Research.
